• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Ibrolipim Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758696

Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Ibrolipim, Inhibitor
Full Product Name
Ibrolipim
Product Synonym Names
NO-1886
Form/Format
Solid. Powder
Purity/Purification
99.47%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
451.25
Solubility
DMSO: 125mg/mL (277.01mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
Br1C19H20N2O4P1
SMILES
CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC
CAS Number
133208-93-2
Target & IC50
Lipoprotein lipase (LPL)
Cell Research
Human THP-1 cells pre-incubated with ox-LDL served as foam cell models. Specific mRNA was quantified using real-time RT-PCR and protein expression using Western blotting. Cellular cholesterol handling was studied using cholesterol efflux experiments and high performance liquid chromatography assays[1]
In Vitro
Ibrolipim (NO-1886; 100mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment,decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue[2]

Structure of Ibrolipim, inhibitor

Ibrolipim Inhibitor – Cat# MBS5758696

Product References and Citations for Ibrolipim, inhibitor

Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31(10):1343-9.
Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31(10):1343-9.
Kano S, Doi M. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats[J]. Metabolism-clinical & Experimental, 2006, 55(2):151-158.
Kano S, Doi M. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats[J]. Metabolism-clinical & Experimental, 2006, 55(2):151-158.
Chen SG, Xiao J, Liu XH,et al.Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31(10):1343-9.

Other Notes

Small volumes of Ibrolipim, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Ibrolipim purchase

MBS5758696 is an inhibitor targeting Ibrolipim.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000